Related Experiment Video
Updated: May 3, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Personalized assessment of hyperuricemia probability in metabolic dysfunction-associated steatotic liver disease:
Yahui Wu1,2, Jinsheng Wang1,2, Yixiang Xing3,4
1Department of Pathology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Background:
Metabolic dysfunction-associated steatotic liver disease is increasingly recognized as a precursor to secondary hyperuricemia, significantly exacerbating metabolic burden. However, reliable tools for early risk stratification in MASLD patients remain limited. This study aimed to develop and validate a robust machine learning-based model to identify factors associated with concurrent hyperuricemia and develop a diagnostic nomogram for MASLD patients.
Methods:
A multicenter retrospective study was conducted involving 530 participants from two independent hospitals. The Least Absolute Shrinkage and Selection Operator regression was employed to screen characteristic variables. Seven machine learning algorithms, including Logistic Regression, Random Forest, and XGBoost, were constructed and compared. A quantitative nomogram was subsequently developed based on the optimal model.
Results:
Six independent risk factors were identified: gender, body mass index, gamma-glutamyl transferase, serum creatinine concentration, serum triglycerides concentration, and the TyG index. Among the evaluated algorithms, the logistic regression model exhibited the superior balance of robustness and interpretability, achieving an area under the curve of 0.93 in the internal validation set and 0.67 in the external validation cohort. The constructed nomogram demonstrated satisfactory calibration and significant clinical utility, as confirmed by decision curve analysis, effectively distinguishing high-risk individuals across diverse populations.
Conclusion:
The novel logistic regression-based nomogram provides a practical, accurate, and cost-effective tool for the personalized risk assessment of concurrent hyperuricemia in MASLD patients, facilitating informed clinical decision-making and management.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

